O	0	4	Role
O	5	7	of
O	8	17	detection
O	18	24	method
O	25	27	in
O	28	38	predicting
O	39	45	breast
O	46	52	cancer
O	53	61	survival
O	61	62	:
O	63	71	analysis
O	72	74	of
O	75	85	randomized
O	86	95	screening
O	96	102	trials
O	102	103	.

O	104	113	Screening
O	114	125	mammography
O	126	133	detects
O	134	140	breast
O	141	148	cancers
O	149	156	earlier
O	157	161	than
O	162	167	those
O	168	176	detected
O	177	192	symptomatically
O	192	193	,
O	194	197	and
O	198	200	so
O	201	217	mammographically
O	218	226	detected
O	227	233	breast
O	234	241	cancers
O	242	246	tend
O	247	249	to
O	250	254	have
O	255	261	better
O	262	271	prognoses
O	271	272	.

O	273	276	The
O	277	279	so
O	279	280	-
O	280	286	called
O	287	292	stage
O	293	298	shift
O	299	303	that
O	304	311	results
O	312	316	from
O	317	323	screen
O	324	333	detection
O	334	336	is
O	337	344	subject
O	345	347	to
O	348	352	lead
O	352	353	-
O	353	357	time
O	358	361	and
O	362	368	length
O	369	375	biases
O	375	376	,
O	377	380	and
O	381	383	so
O	384	391	earlier
O	392	401	detection
O	402	405	may
O	406	409	not
O	410	419	translate
O	420	424	into
O	425	431	longer
O	432	440	survival
O	440	441	.

O	442	444	We
O	445	449	used
O	450	454	data
O	455	459	from
O	460	465	three
O	466	471	large
O	472	478	breast
O	479	485	cancer
O	486	495	screening
O	496	502	trials
O	502	503	-
O	503	504	-
O	504	510	Health
O	511	520	Insurance
O	521	525	Plan
O	526	527	(
O	527	530	HIP
O	530	531	)
O	532	534	of
B-location	535	538	New
I-location	539	543	York
O	544	547	and
O	548	551	two
B-location	552	560	Canadian
O	561	569	National
O	570	576	Breast
O	577	583	Cancer
O	584	593	Screening
O	594	601	Studies
O	602	603	(
O	603	608	CNBSS
O	608	609	)
O	609	610	-
O	610	611	-
O	611	613	to
O	614	625	investigate
O	626	634	survival
O	635	643	benefits
O	644	646	of
O	647	653	breast
O	654	660	cancer
O	661	670	screening
O	671	677	beyond
O	678	683	stage
O	684	689	shift
O	689	690	.

O	691	693	We
O	694	698	also
O	699	706	address
O	707	714	whether
O	715	721	method
O	722	724	of
O	725	734	detection
O	735	737	is
O	738	740	an
O	741	752	independent
O	753	763	prognostic
O	764	770	factor
O	771	773	in
O	774	780	breast
O	781	787	cancer
O	787	788	.

O	789	792	The
O	793	796	HIP
O	797	802	trial
O	803	811	randomly
O	812	820	assigned
O	821	834	approximately
B-total-participants	835	837	62
I-total-participants	837	838	,
I-total-participants	838	841	000
O	842	847	women
O	848	850	to
B-intervention	851	860	screening
O	861	864	and
B-control	865	872	control
O	873	879	groups
O	879	880	.

O	881	884	The
O	885	888	two
O	889	894	CNBSS
O	895	900	trial
O	901	908	cohorts
O	909	914	CNBSS
O	914	915	-
O	915	916	1
O	917	920	and
O	921	926	CNBSS
O	926	927	-
O	927	928	2
O	929	937	included
O	938	939	a
O	940	945	total
O	946	948	of
B-intervention-participants	949	951	44
I-intervention-participants	951	952	,
I-intervention-participants	952	955	970
O	956	961	women
O	962	964	in
O	965	968	the
O	969	978	screening
O	979	984	group
O	985	988	and
B-control-participants	989	991	44
I-control-participants	991	992	,
I-control-participants	992	995	961
O	996	998	in
O	999	1002	the
O	1003	1010	control
O	1011	1016	group
O	1016	1017	.

O	1018	1023	After
O	1024	1033	adjusting
O	1034	1037	for
O	1038	1043	stage
O	1044	1047	and
O	1048	1053	other
O	1054	1059	tumor
O	1060	1075	characteristics
O	1076	1078	in
O	1079	1080	a
O	1081	1084	Cox
O	1085	1097	proportional
O	1098	1105	hazards
O	1106	1111	model
O	1111	1112	,
O	1113	1121	survival
O	1122	1135	distributions
O	1136	1140	were
O	1141	1149	compared
O	1150	1152	by
O	1153	1159	method
O	1160	1162	of
O	1163	1169	breast
O	1170	1176	cancer
O	1177	1186	detection
O	1187	1191	with
O	1192	1196	both
O	1197	1207	univariate
O	1208	1211	and
O	1212	1225	multivariable
O	1226	1234	analyses
O	1234	1235	.

O	1236	1239	All
O	1240	1241	P
O	1242	1248	values
O	1249	1252	are
O	1253	1256	two
O	1256	1257	-
O	1257	1262	sided
O	1262	1263	.

B-outcome	1264	1270	Breast
I-outcome	1271	1278	cancers
I-outcome	1279	1287	detected
I-outcome	1288	1290	by
I-outcome	1291	1300	screening
I-outcome	1301	1312	mammography
O	1313	1316	had
O	1317	1318	a
O	1319	1324	shift
O	1325	1327	in
O	1328	1333	stage
O	1334	1346	distribution
O	1347	1349	to
O	1350	1357	earlier
O	1358	1364	stages
O	1365	1366	(
O	1366	1369	for
O	1370	1373	HIP
O	1373	1374	,
O	1375	1376	P
O	1377	1378	<
O	1379	1380	.
O	1380	1383	001
O	1383	1384	;
O	1385	1388	for
O	1389	1394	CNBSS
O	1394	1395	-
O	1395	1396	1
O	1396	1397	,
O	1398	1399	P
O	1400	1401	=
O	1402	1403	.
O	1403	1405	03
O	1405	1406	;
O	1407	1410	and
O	1411	1414	for
O	1415	1420	CNBSS
O	1420	1421	-
O	1421	1422	2
O	1422	1423	,
O	1424	1425	P
O	1426	1427	<
O	1428	1429	.
O	1429	1432	001
O	1432	1433	)
O	1433	1434	.

O	1435	1440	After
O	1441	1450	adjusting
O	1451	1454	for
O	1455	1460	tumor
O	1461	1465	size
O	1465	1466	,
O	1467	1472	lymph
O	1473	1477	node
O	1478	1484	status
O	1484	1485	,
O	1486	1489	and
O	1490	1497	disease
O	1498	1503	stage
O	1504	1506	in
O	1507	1508	a
O	1509	1512	Cox
O	1513	1525	proportional
O	1526	1533	hazards
O	1534	1539	model
O	1539	1540	,
O	1541	1547	method
O	1548	1550	of
O	1551	1560	detection
O	1561	1564	was
O	1565	1566	a
O	1567	1580	statistically
O	1581	1592	significant
O	1593	1604	independent
O	1605	1614	predictor
O	1615	1617	of
O	1618	1625	disease
O	1625	1626	-
O	1626	1634	specific
O	1635	1643	survival
O	1643	1644	.

O	1645	1653	Patients
O	1654	1658	with
O	1659	1667	interval
O	1668	1675	cancers
O	1676	1679	had
O	1680	1681	a
B-iv-bin-percent	1682	1684	53
I-iv-bin-percent	1684	1685	%
O	1686	1687	(
O	1687	1689	95
O	1689	1690	%
O	1691	1701	confidence
O	1702	1710	interval
O	1711	1712	[
O	1712	1714	CI
O	1714	1715	]
O	1716	1717	=
O	1718	1720	17
O	1720	1721	%
O	1722	1724	to
O	1725	1728	100
O	1728	1729	%
O	1729	1730	)
O	1731	1738	greater
O	1739	1745	hazard
O	1746	1748	of
B-outcome	1749	1754	death
I-outcome	1755	1759	from
I-outcome	1760	1766	breast
I-outcome	1767	1773	cancer
O	1774	1778	than
O	1779	1787	patients
O	1788	1792	with
O	1793	1799	screen
O	1799	1800	-
O	1800	1808	detected
O	1809	1816	cancers
O	1816	1817	,
O	1818	1821	and
O	1822	1830	patients
O	1831	1835	with
O	1836	1842	cancer
O	1843	1845	in
O	1846	1849	the
O	1850	1857	control
O	1858	1864	groups
O	1865	1868	had
O	1869	1870	a
B-cv-bin-percent	1871	1873	36
I-cv-bin-percent	1873	1874	%
O	1875	1876	(
O	1876	1878	95
O	1878	1879	%
O	1880	1882	CI
O	1883	1884	=
O	1885	1887	10
O	1887	1888	%
O	1889	1891	to
O	1892	1894	68
O	1894	1895	%
O	1895	1896	)
O	1897	1904	greater
O	1905	1911	hazard
O	1912	1914	of
O	1915	1920	death
O	1921	1925	than
O	1926	1934	patients
O	1935	1939	with
O	1940	1946	screen
O	1946	1947	-
O	1947	1955	detected
O	1956	1962	cancer
O	1962	1963	.

O	1964	1969	There
O	1970	1973	was
O	1974	1976	an
O	1977	1985	apparent
B-outcome	1986	1994	survival
I-outcome	1995	2002	benefit
O	2003	2009	beyond
O	2010	2015	stage
O	2016	2021	shift
O	2022	2025	for
O	2026	2034	patients
O	2035	2039	with
O	2040	2046	screen
O	2046	2047	-
O	2047	2055	detected
O	2056	2062	breast
O	2063	2070	cancers
O	2071	2079	compared
O	2080	2084	with
O	2085	2093	patients
O	2094	2098	with
O	2099	2105	breast
O	2106	2113	cancers
O	2114	2122	detected
O	2123	2132	otherwise
O	2132	2133	.

O	2134	2140	Method
O	2141	2143	of
O	2144	2153	detection
O	2154	2161	appears
O	2162	2164	to
O	2165	2167	be
O	2168	2170	an
O	2171	2180	important
O	2181	2191	prognostic
O	2192	2198	factor
O	2198	2199	,
O	2200	2204	even
O	2205	2210	after
O	2211	2220	adjusting
O	2221	2224	for
O	2225	2230	known
O	2231	2236	tumor
O	2237	2252	characteristics
O	2252	2253	.

O	2254	2258	This
O	2259	2266	finding
O	2267	2275	suggests
O	2276	2280	that
O	2281	2289	clinical
O	2290	2299	trialists
O	2300	2306	should
O	2307	2316	routinely
O	2317	2324	collect
O	2325	2336	information
O	2337	2342	about
O	2343	2349	method
O	2350	2352	of
O	2353	2362	detection
O	2362	2363	.
